2014

PPD, ERT partner to enhance drug development

Wednesday, December 17, 2014

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., and ERT, a Philadelphia, Pa.-based provider of patient safety and efficacy data collection solutions, have partnered to facilitate delivery of ERT’s comprehensive solutions for patient safety and efficacy endpoint data collection to help biopharmaceutical clients conduct clinical trials in a more efficient and cost-effective manner.

[Read More]

Infraredx, Massachusetts General Hospital collaborate on cardiovascular imaging devices

Wednesday, December 17, 2014

Infraredx, a Burlington, Mass.-based cardiovascular imaging company, is collaborating with Massachusetts General Hospital (MGH) and coronary imaging researcher Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.

[Read More]

CRF Health partners with EuroQol to become a preferred eCOA provider

Wednesday, December 17, 2014

CRF Health, a global provider of eCOA solutions for the life sciences industry based in Plymouth Meeting, Pa., has inked an agreement with EuroQol to launch the EQ-5D web system on its TrialMax Web software platform. CRF Health has become the first eCOA provider to be granted permission to host the EQ-5D web version for use in clinical trials. CRF Health now is uniquely positioned to provide a single solution for eCOA that combines the benefits of EQ-5D to make data collection faster and optimize the valuation of health outcomes. 

[Read More]

ClinicalRM tests convalescent plasma therapy for Ebola treatment

Monday, December 15, 2014

Clinical Research Management (ClinicalRM), a full-service CRO with headquarters in Ohio, has announced that the clinical trial evaluating the safety and efficacy of Ebola convalescent plasma (ECP) for the treatment of Ebola virus disease (EVD) in Liberia has commenced. The first donor survivors at the ELWA Hospital 2 unit in Monrovia, Liberia have undergone plasmapheresis. The donated convalescent plasma was transferred to a Liberian patient with EVD in an effort to help them combat this disease. The ClinicalRM trial is being funded through a grant from the Bill & Melinda Gates Foundation.

[Read More]

Parexel ClinPhone RTSM named interactive response technology leader

Monday, December 15, 2014

Parexel International, a global biopharmaceutical services provider, has announced that its randomization and trial supply management (RTSM) services, ClinPhone RTSM, ranked as the leader of Interactive Response Technology (IRT), according to a new global survey of pharmaceutical and biotechnology companies by Industry Standard Research (ISR). ClinPhone RTSM also was cited as the most preferred and widely used IRT solution.

[Read More]

OPKO, Pfizer ink global agreement for human growth hormone

Monday, December 15, 2014

OPKO Health, a multinational biopharmaceutical and diagnostics company, and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age.

[Read More]